 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...1920212223242526272829...4748» |
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Frontline therapy of anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib in patients with newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study. (Available On Demand; 480a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5435;
P2
Key secondary endpoints include overall response rate, disease control rate per RECIST1.1, overall survival, safety. The study began enrolling patients in August 2021 and is ongoing.
- Keytruda (pembrolizumab) / Merck (MSD), Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of pembrolizumab in combination with anlotinib in the treatment of refractory or recurrent high-grade serous ovarian cancer: A phase 2 nonrandomized clinical trial. (Available On Demand; 422) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5374;
The anlotinib-pembrolizumab combination showed promising efficacy and favorable safety as treatment for refractory or recurrent High-Grade Serous Ovarian Cancer. The ARID1A are potential biomarkers for predicting the efficacy of this novel regimen.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer. (Available On Demand; 415) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5367;
Anlotinib plus sintilimab showed a long-term survival benefit for patients with recurrent advanced cervical cancer. Additional investigations in larger randomized controlled trials are warranted in the future.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase 2 study of anlotinib in patients with metastatic pheochromocytoma/paraganglioma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5247;
P2
Additional investigations in larger randomized controlled trials are warranted in the future. The preliminary results of this study indicated that anlotinib is a potential choice for the treatment of MPP with the high ability on disease control and well tolerability.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4500;
The preliminary results of this study indicated that anlotinib is a potential choice for the treatment of MPP with the high ability on disease control and well tolerability. Anlotinib combined with temozolomide is efficacious and well-tolerated in recurrent GBM patients.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4473;
P1/2
The efficacy was impressive in that the median OS had exceeded 18m and the safety profile was favorable. The positive-controlled study was ongoing.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib in combination with dose-intense temozolomide for the recurrent or progressive glioblastoma after STUPP regimen. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4472;
P2
Preliminary results indicated that the efficacy was promising for those miserable pts with worse prognosis factors. Further investigation was ongoing.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A randomized phase II study of anlotinib combined with STUPP versus STUPP alone in patients with newly diagnosed glioblastoma (GBM). (Available On Demand; 414a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4434;
P1/2, P2
Secondary endpoints include overall survival (OS), PFS accessed by investigators, overall response rate (ORR), severity and frequency of AEs (CTCAE V5.0), and quality of life (QOL). The disease control rate (DCR) and duration of response (DOR) will also be explored.
- lobaplatin (D19466) / AEterna Zentaris, Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: Efficacy, safety and biomarker analysis. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3387;
Pts with clinical stage II/III TNBC were to be treated with 5 cycles of anlotinib (12mg, d1-14, q3w) plus 6 cycles of taxanes (docetaxel 75 mg/m2 or nab-paclitaxel 260 mg/m2, d1, q3w) and lobaplatin (30 mg/m2, d1, q3w), followed by surgery. The addition of anlotinib to neoadjuvant chemotherapy showed manageable toxicity and promising antitumor activity for patients with early-stage TNBC.
- Baize'an (tislelizumab) / BeiGene, Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study. (Available On Demand; 383b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3315;
P2
A sample size of 32 patients was estimated to provide a 80% power to detect a difference of 25% in pCR at a significance level of α = 0.05. The study was initiated in August 2021.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Role of anlotinib in the treatment of early advanced osteosarcoma of limbs in children. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3200;
Combination of anlotinib with first-line chemotherapy can shrink the tumor, improve limb salvage rate for children with early advanced osteosarcoma, and delay disease progression for children with recurrence and metastasis after radical surgery. The toxicity of anlotinib combined with first-line chemotherapy were tolerated which is expected to be a new approach for the treatment of early advanced osteosarcoma.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib rechallenge combined with immune checkpoint inhibitor for advanced soft tissue sarcoma after the failure of anlotinib. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3195;
Two cases (20%) were observed a partial response, including anlotinib plus nivolumab for a leiomyosarcoma and anlotinib plus toripalimab for an angiosarcoma. ICIs plus anlotinib rechallenges maybe a potential treatment for advanced STS patients after progression on anlotinib with acceptable adverse events.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Long-term efficacy and safety of anlotinib in advanced sarcomas. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3168;
Besides, anlotinib combined with anti-PD1 therapy has better therapeutic efficacy for specific diseases such as ASPS and ES. Anlotinib combined with chemotherapy has therapeutic efficacy for SS, LMS, FS, and RMS.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The efficiency of anlotinib in osteosarcoma with chemoresistance: Exploratory therapy based on PDX models and next-generation sequencing. (Available On Demand; 432) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3100;
Anlotinib combined with chemotherapy has therapeutic efficacy for SS, LMS, FS, and RMS. Based on the results of PDX models and NGS, we suggested that osteosarcoma with high expression of VEGFR-2 or/and PDGFR-β was sensitive to anlotinib, which was alternative for patients progressed during NAC.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with pemetrexed and carboplatin as first-line treatment in driver-gene negative advanced non-squamous non-small cell lung cancer: ALTER L012. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3046;
P1
This study finds that anlotinib plus pemetrexed and carboplatin followed by anlotinib plus pemetrexed maintenance therapy might be a promising treatment for patients with wild-type EGFR/ALK advanced nsq-NSCLC. The combination was well tolerated, and the AEs were manageable.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase Ib/IIa study evaluating the safety and clinical activity of osimeritinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients (AUTOMAN). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2998;
P1/2
Osimertinib in combination with anlotinib as first-line treatment for naïve EGFRm advanced NSCLC patients showed encouraging antitumor activity with manageable safety profile. The study is ongoing and more results will be updated in the future.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A real-world study update: Efficacy and safety of anlotinib for advanced non-small cell lung cancer. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2956;
The updated results showed that anlotinib prolonged not only PFS but also OS significantly with a favorable safety profile, especially for OS benefits in third-line or later treatment. These data also indirectly revealed that anlotinib is a promising treatment option for patients with advanced NSCLC despite of treatment line in the real world.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
In vitro and in vivo investigations of anlotinib in bladder cancer treatment. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2577;
Anlotinib could repress the proliferation, migration and invasion of bladder cancer cells by inhibiting the phosphorylation of Erk1/2 and AKT, and the suppression VEGF-a expression, whose effects was better than erdafitinib in bladder cancer with FGFR3 fusion mutation. Therefore, anlotinib might be a potential novel targeted agent to treat the bladder cancer patients with FGFR3 fusion mutations, and clinical trials are needed for further investigation.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma. (Available On Demand; 89a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2528;
P2
2022. Research Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma. (Available On Demand; 58) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2497;
An effective treatment strategy for cisplatin-ineligible patients and for patients unable to receive chemotherapy is an important unmet clinical need. Penpulimab in combination with anlotinib in pts with la/mUC showed encouraging efficacy and satisfactory safety.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib for patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2410;
P2
Anlotinib monotherapy seemed to be a promising option for pts with R/M NPC who were heavily treated. The survival benefits were impressive and the toxicity was tolerable.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib in radioactive iodine-refractory differentiated thyroid cancer and the usefulness of SUVmax as an prognostic indicator. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2383;
This study confirmed the efficacy of Anlotinib with a high disease control rate. SUVmax can be used as an indicator to predict the therapeutic effect of Anlotinib in RAIR-DTC patients.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2382;
P2
This preliminary analysis indicated that penpulimab plus gemcitabine and anlotinib had promising efficacy and favorable tolerance profile as first-line treatment for M NPC. Further investigate is ongoing.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The effect of anlotinib on unresectable differentiated thyroid cancer (T4): A retrospective study. (Available On Demand; 87) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2329;
Further investigate is ongoing. Anlotinib demonstrated antitumor activity in the treatment of unresectable T4 PTC; Juvenile PTC patients also response to Anlotinib treatment; Anlotinib treatment was tolerable in T4 PTC patients.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study. (Available On Demand; 19) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2261;
P2
The combination of penpulimab and anlotinib demonstrated promising efficacy and manageable toxicities in R/M HNSCC pts who failed standard first-line therapy. Further investigation is warranted.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Real-world effectiveness of anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2228;
P
Anlotinib plus PD-1 inhibitors in chemo-free therapy for advanced or metastatic esophageal cancer was active and showed excellent tumor response and was generally well tolerated. Further investigation is required in a larger real-world cohort to validate the benefit of anlotinib plus PD-1 inhibitor in esophageal cancer.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2219;
Preliminary results suggested that anlotinib combined with nab-paclitaxel and cisplatin in neoadjuvant treatment of ESCC exhibited encouraging efficacy and manageable adverse events. The conclusion should be validated in more patients included subsequently.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery—A single-arm, multicenter, phase II clinical trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2218;
P2
The conclusion should be validated in more patients included subsequently. The update results suggested that anlotinib combined with TACE as adjuvant therapy in HCC pts at high recurrence risk exhibited promising clinical benefit and favorable safety profile, and the results needed to be confirmed in trials continued subsequently.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
APEC: Efficacy and toxicity of anlotinib plus PD-1 inhibitors as later-line therapy in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A retrospective real-world study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2197;
To our knowledge, this is the first analysis to demonstrate the benefits of anlotinib plus PD-1 inhibitors as later-line therapy in ESCC. The data suggests that anlotinib plus PD-1 inhibitor is a new treatment in ESCC pts, and further validation in a larger cohort is needed.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib for the treatment of locally advanced or metastatic pheochromocytoma and paraganglioma: A retrospective study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2196;
Eligible pts received anlotinib monotherapy or in combination with peptide receptor radionuclide therapy (PRRT) or 131I-MIBG. This single-center retrospective study indicated that anlotinib monotherapy or in combination with radionuclide therapy showed promising efficacy and favourable safety profile in the treatment of LA/M PCC and PGL, which is worthy of further exploration.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
A phase Ib study of anlotinib plus TQB2450 as a second-line investigational therapy in advanced hepatocellular carcinoma (aHCC). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2168;
P1/2
Anlotinib plus TQB2450 was tolerable and showed preliminary antitumor activity in pre-treated aHCC. Further investigation in larger population is warranted.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of anlotinib with PD-1 blockades in the treatment of advanced biliary tract cancer: A real-world study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2064;
P
Present study indicated that the combination of anlotinib and PD-1 blockades exhibited potential efficacy and manageable adverse events in the treatment of advanced BTC in the real world. The conclusion should be validated in more patients included subsequently.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC. (Available On Demand; 87) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1938;
P2
In pts with advanced BTC, sintilimab + anlotinib + GemCis could improve OS and PFS vs GemCis with manageable safety, indicating sintilimab + anlotinib + GemCis may be a new first-line standard of care regimen. Research Sponsor: Innoventbio Biologics, Inc, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer. (Available On Demand; 65) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1916;
Research Sponsor: Innoventbio Biologics, Inc, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The combination of anlotinib and toripalimab were demonstrated promising anti-tumor activity in advanced biliary cancer.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1476;
The update results suggested that anlotinib combined with XELOX as first line regimen followed by anlotinib monotherapy showed favorable anti-tumor activity and manageable safety for patients with mCRC. And the conclusions needed to be confirmed in randomized study continued subsequently.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1249;
P2
The combination of eribulin and anlotinib showed a better treatment response and tolerable toxicity in HER2-negative metastatic breast cancer patients. Further studies enrolling more patients are still needed.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study. (Available On Demand; 471) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1180;
P2
Further studies enrolling more patients are still needed. Eribulin plus anlotinib was associated with a significantly better DCR, ORR and PFS than eribulin monotherapy in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
- APL-502 / Apollomics
Genomic landscape and peripheral blood biomarkers of advanced triple-negative breast cancer treated with immune checkpoint blockade: An exploratory analysis of the TQB2450-Ib-07 trial. (Available On Demand; 458) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1167;
P1
For aTNBC treated with ICI, MSAF tended to be a robust indicator for both PFS and clinical response. NLR week 2/0 presented a favorable profile indicative of PFS as well as a strong predictor for clinical responsiveness of patients with aTNBC receiving immune checkpoint blockade.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - Apr 27, 2022
P2, N=31, Recruiting, Sponsor: Peking Union Medical College Hospital
NLR week 2/0 presented a favorable profile indicative of PFS as well as a strong predictor for clinical responsiveness of patients with aTNBC receiving immune checkpoint blockade. Not yet recruiting --> Recruiting
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P3 trial, Metastases: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). (clinicaltrials.gov) - Apr 25, 2022
P3, N=390, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial, Real-world evidence, Real-world, Metastases: TACE Combined With Penpulimab and Anlotinib for Advanced HCC (clinicaltrials.gov) - Apr 25, 2022
P2/3, N=230, Not yet recruiting, Sponsor: Zhongda Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report. (Pubmed Central) - Apr 22, 2022
P2
(4) Salvage HSRT combined with anlotinib showed a favourable outcome and acceptable toxicity for rGBM. A prospective phase II study (NCT04197492) is ongoing to further investigate the regimen.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study. (Pubmed Central) - Apr 21, 2022
Anlotinib combined with PD-1 blockades demonstrated promising efficacy and tolerable safety profile for patients with previously treated advanced EOC preliminarily. The conclusion should be confirmed in more patients with advanced EOC subsequently.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. (Pubmed Central) - Apr 20, 2022
PI3K inhibitors could reverse anlotinib resistance in OS, limiting OS cell development in combination with anlotinib. Our findings rationalize further studies on the applications of PI3K inhibitors that can be clinically used in anlotinib-refractory OS management.
- || Tyvyt (sintilimab) / Eli Lilly
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Sintilimab for the treatment of non-small cell lung cancer. (Pubmed Central) - Apr 20, 2022
In general, sintilimab and its combinatorial plans were effective and well tolerated, but the treatment requires appropriate timing; pathologic responses can be surrogate endpoints for neoadjuvant immunotherapy, while more effective biomarkers are warranted. This study provides an overview of sintilimab-based clinical trials on NSCLC, and may support further investigation of sintilimab in future clinical trials.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Retrospective data, Journal: Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. (Pubmed Central) - Apr 19, 2022
There were no grade 5 AE. In conclusion, anlotinib increased PFS compared with placebo in patients with SCLC and liver metastasis.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
PK/PD data, Journal: Application of Physiologically Based Pharmacokinetic Modelling for the Prediction of Drug-drug Interactions Involving Anlotinib as a Perpetrator of Cytochrome P450 enzymes. (Pubmed Central) - Apr 19, 2022
As a result, the marginal plasma exposure changes of typical CYP3A and CYP2C9 substrates were less than the bioequivalence threshold, indicating that anlotinib has a very low potential of causing clinically meaningful DDI through the inhibition of several major CYP enzymes. According to the FDA's latest guideline on DDIs, the established model with the simulation results may support the revision of anlotinib labelling without further clinical studies, lifting unnecessary restrictions on anlotinib regimens.
- | Irene (pyrotinib) / Jiangsu Hengrui Medicine, Gilotrif (afatinib) / Boehringer Ingelheim
Journal: Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report. (Pubmed Central) - Apr 19, 2022
After computed tomography showed tumor enlargement in October 2021, anlotinib was added to the present treatment. This case suggests that pyrotinib may provide a novel effective treatment option for HER2-amplified lung cancer.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Apr 19, 2022
Our results revealed a U-shaped relationship between BMI and risk of death in patients receiving anlotinib for advanced NSCLC. More importantly, obesity (BMI ≥28 kg/m) might be a potential predictor of use of anlotinib in advanced NSCLC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors. (Pubmed Central) - Apr 19, 2022
For heavily pretreated pediatric solid tumors, anlotinib monotherapy and its combination with chemotherapy may be an effective treatment option with tolerable adverse events. It is necessary to monitor blood pressure when using anlotinib in children.